ALTASCIENCES CLINICAL KANSAS INC - INVESTIGATIONAL AGENT SINGLE ASCENDING DOSE SAFETY, TOLERABILITY, AND PK STUDY. SEPTEMBER 3, 2024 TO MARCH 2, 2026. N01DA-23-8935

On Feb 20, 2026, Department of Health and Human Services obligated $1,724,198.59 to ALTASCIENCES CLINICAL KANSAS INC for investigational agent single ascending dose safety, tolerability, and pk study. september 3, 2024 to march 2, 2026. n01da-23-8935. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition. Performance is located in OVERLAND PARK, KS. The contract is scheduled through Mar 10, 2027 — approximately 11 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.